Goldman Sachs Group Inc. Lowers Stock Position in Guardian Pharmacy Services, Inc. $GRDN

Key Points

• Goldman Sachs Group Inc. has drastically reduced its stake in Guardian Pharmacy Services by 90.9%, leaving it with only 15,515 shares worth approximately $330,000.
• Several institutional investors have increased their holdings in Guardian Pharmacy Services, with Peregrine Capital Management LLC boosting its stake by 56.1% during the same period.
• Analysts are optimistic about Guardian Pharmacy Services, with Wall Street Zen upgrading the stock to a "strong-buy" and a target price increase from $28.00 to $30.00 by Truist Financial.

Goldman Sachs Group Inc. reduced its position in Guardian Pharmacy Services, Inc. (NYSE:GRDN - Free Report) by 90.9% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 15,515 shares of the company's stock after selling 155,351 shares during the period. Goldman Sachs Group Inc.'s holdings in Guardian Pharmacy Services were worth $330,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Peregrine Capital Management LLC boosted its stake in Guardian Pharmacy Services by 56.1% in the first quarter. Peregrine Capital Management LLC now owns 176,539 shares of the company's stock valued at $3,753,000 after acquiring an additional 63,464 shares during the period. Royce & Associates LP raised its holdings in Guardian Pharmacy Services by 27.6% during the 1st quarter. Royce & Associates LP now owns 273,068 shares of the company's stock worth $5,805,000 after purchasing an additional 59,068 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Guardian Pharmacy Services by 14.2% during the first quarter. Wellington Management Group LLP now owns 464,924 shares of the company's stock worth $9,884,000 after acquiring an additional 57,924 shares in the last quarter. New York State Common Retirement Fund grew its holdings in Guardian Pharmacy Services by 16.1% during the first quarter. New York State Common Retirement Fund now owns 323,257 shares of the company's stock worth $6,872,000 after purchasing an additional 44,709 shares during the period. Finally, Premier Fund Managers Ltd acquired a new position in Guardian Pharmacy Services in the 1st quarter valued at $435,000.

Analyst Ratings Changes

A number of research analysts have issued reports on GRDN shares. Wall Street Zen upgraded Guardian Pharmacy Services from a "hold" rating to a "strong-buy" rating in a research note on Sunday, August 17th. Truist Financial boosted their target price on Guardian Pharmacy Services from $28.00 to $30.00 and gave the company a "buy" rating in a research report on Friday. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat, Guardian Pharmacy Services has an average rating of "Buy" and an average price target of $26.33.

Guardian Pharmacy Services Stock Up 2.5%

GRDN stock opened at $26.08 on Friday. Guardian Pharmacy Services, Inc. has a fifty-two week low of $15.52 and a fifty-two week high of $30.39. The company has a market capitalization of $1.65 billion and a P/E ratio of -17.16. The company has a 50-day simple moving average of $24.57 and a 200 day simple moving average of $22.89.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.